| Peer-Reviewed

Value of Prognostic Nutritional Index for Predicting Survival in Patients with Advanced Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy

Received: 11 October 2022     Accepted: 7 November 2022     Published: 16 November 2022
Views:       Downloads:
Abstract

Background: Esophageal cancer is the sixth leading cause of cancer-related death worldwide. Despite the advances in the surgical approach, chemotherapy and radiotherapy regimens, and the continuous development of biological agents, survival outcomes for these patients remain low. The identification of new biomarkers capable of predicting worse survival regardless of the clinical stage is necessary. Purpose: The aim of this study is to evaluate the association between Prognostic Nutritional Index (PNI) and overall survival in patients with advanced squamous esophageal carcinoma. Methods: A retrospective and observational study was conducted in patients with diagnosis of advanced esophageal squamous cell carcinoma treated at Hermanos Ameijeiras Hospital from January 2013 to June 2019. The PNI was calculated using the following formula: 10 x Albumin (g/dL) + 0.005 x Lymphocyte counts (x109). Results: A total of 94 patients were enrolled in this study. The area under the curve (AUC) was 0,583 and the optimal cut-off value was 40. PNI was significantly associated with hemoglobin level, platelet count, total lymphocyte count, neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), and therapeutic response. PNI was negatively correlated with inflammatory indexes. Patients with PNI ˂40 had a significantly shorter median overall survival compared to patients with PNI ≥40. Multivariate analysis identified that ECOG ≥1, platelet count, NLR≥4 and PNI˂40 were independent prognostic factors for poor overall survival. Conclusion: The present study demonstrated that pretreatment PNI is a useful marker for predicting survival outcome in patients with advanced esophageal squamous cell carcinoma.

Published in Journal of Cancer Treatment and Research (Volume 10, Issue 3)
DOI 10.11648/j.jctr.20221003.12
Page(s) 31-37
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Esophageal Cancer, Albumin, Lymphocyte, Inflammation, Nimotuzumab

References
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424. DOI: 10.3322/caac.21492
[2] Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020; 50 (1): 12-20. doi: 10.1007/s00595-019-01878-7.
[3] Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 2018; 41 (3): 210-215. doi: 10.1016/j.asjsur.2016.10.005.
[4] Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Immunol. 2017; 18 (8): 843-850. doi: 10.1038/ni.3754.
[5] Jiang Y, Xu D, Song H, et al. Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis. BMJ Open. 2021; 11 (9): e048324. doi: 10.1136/bmjopen-2020-048324.
[6] Hyder J, Boggs DH, Hanna A, et al. Changes in neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios during chemoradiation predict for survival and pathologic complete response in trimodality esophageal cancer patients. J Gastrointest Oncol. 2016; 7 (2): 189-95. doi: 10.3978/j.issn.2078-6891.2015.080.
[7] Li KJ, Xia XF, Su M, et al. Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy. BMC Cancer. 2019; 19 (1): 1004. doi: 10.1186/s12885-019-6157-4.
[8] Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi. 1984; 85 (9): 1001-5. Japanese.
[9] Cadwell JB, Afonso AM, Shahrokni A. Prognostic nutritional index (PNI), independent of frailty is associated with six-month postoperative mortality. J Geriatr Oncol. 2020; 11 (5): 880-884. doi: 10.1016/j.jgo.2020.03.013.
[10] Xishan Z, Ye Z, Feiyan M, et al. The role of prognostic nutritional index for clinical outcomes of gastric cancer after total gastrectomy. Sci Rep. 2020; 10 (1): 17373. doi: 10.1038/s41598-020-74525-8.
[11] Yan L, Nakamura T, Casadei-Gardini A, et al. Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review. Ann Transl Med. 2021; 9 (21): 1630. doi: 10.21037/atm-21-4528.
[12] Di Fiore A, Lecleire S, Gangloff A, et al. Impact of nutritional parameter variations during definitive chemoradiotherapy in locally advanced oesophageal cancer. Dig Liver Dis. 2014; 46 (3): 270-5. doi: 10.1016/j.dld.2013.10.016.
[13] Takeda K, Umezawa R, Takahashi N, et al. Impact of change in serum albumin level during and after chemoradiotherapy in patients with locally advanced esophageal cancer. Esophagus. 2018; 15 (3): 190-197. doi: 10.1007/s10388-018-0612-1.
[14] Takao K, Konishi H, Fujiwara H, et al. Clinical significance of prognostic nutritional index in the treatment of esophageal squamous cell carcinoma. In Vivo. 2020; 34 (6): 3451-3457. doi: 10.21873/invivo.12184.
[15] Nassri A, Zhu H, Wang DH, et al. Serum albumin at diagnosis is an independent predictor of early mortality in veteran patients with esophageal cancer. Nutr Cancer. 2018; 70 (8): 1246-1253. doi: 10.1080/01635581.2018.1512639.
[16] Aoyagi T, Terracina KP, Raza A, et al. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015; 7 (4): 17-29. doi: 10.4251/wjgo.v7.i4.17.
[17] Xiang ZJ, Hu T, Wang Y, et al. Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC). Biosci Rep. 2020; 40 (6): BSR20201190. doi: 10.1042/BSR20201190.
[18] Qi Q, Song Q, Cheng Y, et al. Prognostic significance of preoperative prognostic nutritional index for overall survival and postoperative complications in esophageal cancer patients. Cancer Manag Res. 2021; 13: 8585-8597. doi: 10.2147/CMAR.S333190.
[19] Feng JF, Chen QX. Significance of the prognostic nutritional index in patients with esophageal squamous cell carcinoma. Ther Clin Risk Manag. 2014; 10: 1-7. doi: 10.2147/TCRM.S56159.
[20] Xiao FK, Wang L, Zhang WC, Wang LD, Zhao LS. Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival in Esophageal Squamous Cell Carcinoma Patients. Nutr Cancer. 2021; 73 (2): 215-220. doi: 10.1080/01635581.2020.1757129.
[21] Zhang H, Shang X, Ren P, Gong L, Ahmed A, Ma Z, Ma R, Wu X, Xiao X, Jiang H, Tang P, Yu Z. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. J Cell Physiol. 2019; 234 (2): 1794-1802. doi: 10.1002/jcp.27052.
[22] Xiao L, Lyu J, Liu X, et al. Clinical application value of the prognostic nutritional index for predicting survival in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy or radiotherapy. Nutr Cancer. 2021; 73 (10): 1933-1940. doi: 10.1080/01635581.2020.1817511.
[23] Nakatani M, Migita K, Matsumoto S, et al. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy. Dis Esophagus. 2017; 30 (8): 1-7. doi: 10.1093/dote/dox020.
[24] Matsumoto Y, Zhou Q, Kamimura K, et al. The prognostic nutrition index predicts the development of hematological toxicities in and the prognosis of esophageal cancer patients treated with cisplatin plus 5-fluorouracil chemotherapy. Nutr Cancer. 2018 Apr; 70 (3): 447-452. doi: 10.1080/01635581.2018.1445765.
[25] Yoshida N, Baba Y, Shigaki H, et al. Preoperative nutritional assessment by controlling nutritional status (CONUT) is useful to estimate postoperative morbidity after esophagectomy for esophageal cancer. World J Surg. 2016; 40 (8): 1910-7. doi: 10.1007/s00268-016-3549-3.
[26] Barker HE, Paget JT, Khan AA, et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015; 15 (7): 409-25. doi: 10.1038/nrc3958.
[27] Surace L, Scheifinger NA, Gupta A, et al. Radiotherapy supports tumor-specific immunity by acute inflammation. Oncoimmunology. 2015; 5 (1): e1060391. doi: 10.1080/2162402X.2015.1060391
Cite This Article
  • APA Style

    Mayte Lima Pérez, Jorge Luis Soriano García, Jorge Luis Soriano-Lorenzo, Vilma Fleites Calvo, Masiel González Meisozo, et al. (2022). Value of Prognostic Nutritional Index for Predicting Survival in Patients with Advanced Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy. Journal of Cancer Treatment and Research, 10(3), 31-37. https://doi.org/10.11648/j.jctr.20221003.12

    Copy | Download

    ACS Style

    Mayte Lima Pérez; Jorge Luis Soriano García; Jorge Luis Soriano-Lorenzo; Vilma Fleites Calvo; Masiel González Meisozo, et al. Value of Prognostic Nutritional Index for Predicting Survival in Patients with Advanced Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy. J. Cancer Treat. Res. 2022, 10(3), 31-37. doi: 10.11648/j.jctr.20221003.12

    Copy | Download

    AMA Style

    Mayte Lima Pérez, Jorge Luis Soriano García, Jorge Luis Soriano-Lorenzo, Vilma Fleites Calvo, Masiel González Meisozo, et al. Value of Prognostic Nutritional Index for Predicting Survival in Patients with Advanced Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy. J Cancer Treat Res. 2022;10(3):31-37. doi: 10.11648/j.jctr.20221003.12

    Copy | Download

  • @article{10.11648/j.jctr.20221003.12,
      author = {Mayte Lima Pérez and Jorge Luis Soriano García and Jorge Luis Soriano-Lorenzo and Vilma Fleites Calvo and Masiel González Meisozo and Dunia Morales Morgado and Raidel Rodríguez Barrios and Carlos Domínguez Álvarez},
      title = {Value of Prognostic Nutritional Index for Predicting Survival in Patients with Advanced Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy},
      journal = {Journal of Cancer Treatment and Research},
      volume = {10},
      number = {3},
      pages = {31-37},
      doi = {10.11648/j.jctr.20221003.12},
      url = {https://doi.org/10.11648/j.jctr.20221003.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20221003.12},
      abstract = {Background: Esophageal cancer is the sixth leading cause of cancer-related death worldwide. Despite the advances in the surgical approach, chemotherapy and radiotherapy regimens, and the continuous development of biological agents, survival outcomes for these patients remain low. The identification of new biomarkers capable of predicting worse survival regardless of the clinical stage is necessary. Purpose: The aim of this study is to evaluate the association between Prognostic Nutritional Index (PNI) and overall survival in patients with advanced squamous esophageal carcinoma. Methods: A retrospective and observational study was conducted in patients with diagnosis of advanced esophageal squamous cell carcinoma treated at Hermanos Ameijeiras Hospital from January 2013 to June 2019. The PNI was calculated using the following formula: 10 x Albumin (g/dL) + 0.005 x Lymphocyte counts (x109). Results: A total of 94 patients were enrolled in this study. The area under the curve (AUC) was 0,583 and the optimal cut-off value was 40. PNI was significantly associated with hemoglobin level, platelet count, total lymphocyte count, neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), and therapeutic response. PNI was negatively correlated with inflammatory indexes. Patients with PNI ˂40 had a significantly shorter median overall survival compared to patients with PNI ≥40. Multivariate analysis identified that ECOG ≥1, platelet count, NLR≥4 and PNI˂40 were independent prognostic factors for poor overall survival. Conclusion: The present study demonstrated that pretreatment PNI is a useful marker for predicting survival outcome in patients with advanced esophageal squamous cell carcinoma.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Value of Prognostic Nutritional Index for Predicting Survival in Patients with Advanced Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy
    AU  - Mayte Lima Pérez
    AU  - Jorge Luis Soriano García
    AU  - Jorge Luis Soriano-Lorenzo
    AU  - Vilma Fleites Calvo
    AU  - Masiel González Meisozo
    AU  - Dunia Morales Morgado
    AU  - Raidel Rodríguez Barrios
    AU  - Carlos Domínguez Álvarez
    Y1  - 2022/11/16
    PY  - 2022
    N1  - https://doi.org/10.11648/j.jctr.20221003.12
    DO  - 10.11648/j.jctr.20221003.12
    T2  - Journal of Cancer Treatment and Research
    JF  - Journal of Cancer Treatment and Research
    JO  - Journal of Cancer Treatment and Research
    SP  - 31
    EP  - 37
    PB  - Science Publishing Group
    SN  - 2376-7790
    UR  - https://doi.org/10.11648/j.jctr.20221003.12
    AB  - Background: Esophageal cancer is the sixth leading cause of cancer-related death worldwide. Despite the advances in the surgical approach, chemotherapy and radiotherapy regimens, and the continuous development of biological agents, survival outcomes for these patients remain low. The identification of new biomarkers capable of predicting worse survival regardless of the clinical stage is necessary. Purpose: The aim of this study is to evaluate the association between Prognostic Nutritional Index (PNI) and overall survival in patients with advanced squamous esophageal carcinoma. Methods: A retrospective and observational study was conducted in patients with diagnosis of advanced esophageal squamous cell carcinoma treated at Hermanos Ameijeiras Hospital from January 2013 to June 2019. The PNI was calculated using the following formula: 10 x Albumin (g/dL) + 0.005 x Lymphocyte counts (x109). Results: A total of 94 patients were enrolled in this study. The area under the curve (AUC) was 0,583 and the optimal cut-off value was 40. PNI was significantly associated with hemoglobin level, platelet count, total lymphocyte count, neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), and therapeutic response. PNI was negatively correlated with inflammatory indexes. Patients with PNI ˂40 had a significantly shorter median overall survival compared to patients with PNI ≥40. Multivariate analysis identified that ECOG ≥1, platelet count, NLR≥4 and PNI˂40 were independent prognostic factors for poor overall survival. Conclusion: The present study demonstrated that pretreatment PNI is a useful marker for predicting survival outcome in patients with advanced esophageal squamous cell carcinoma.
    VL  - 10
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Digestive Tumors Division, Department of Clinical Oncology, Hermanos Ameijeiras Hospital, Havana, Cuba

  • Digestive Tumors Division, Department of Clinical Oncology, Hermanos Ameijeiras Hospital, Havana, Cuba

  • Digestive Tumors Division, Department of Clinical Oncology, Hermanos Ameijeiras Hospital, Havana, Cuba

  • Digestive Tumors Division, Department of Clinical Oncology, Hermanos Ameijeiras Hospital, Havana, Cuba

  • Digestive Tumors Division, Department of Clinical Oncology, Hermanos Ameijeiras Hospital, Havana, Cuba

  • Digestive Tumors Division, Department of Clinical Oncology, Hermanos Ameijeiras Hospital, Havana, Cuba

  • Digestive Tumors Division, Department of Clinical Oncology, Hermanos Ameijeiras Hospital, Havana, Cuba

  • Sections